ISB News

The Rise of Open Proteomics

Researchers at EMBL-EBI, Institute for Systems Biology and other partnering organizations have launched ProteomeXchange, a public portal for exchanging proteomics data generated from mass-spectrometry experiments and other related information. From the EMBL-EBI-issued press release:

Eric Deutsch, head of PeptideAtlas at the Institute for Systems Biology in the U.S., says: “I’m certain that the ProteomeXchange system is already leading to greater awareness and reuse of publicly available datasets. I’m regularly contacted by people who want to explore new data they’ve heard about through our alert system, and am pleased to see so much growth in this area of science.” Read full press release.

As part of the launch, the consortium also published a correspondence piece in Nature Biotechnology (published online on March 10, 2014). An excerpt:

"There is a growing trend toward public dissemination of proteomics data, which is facilitating the assessment, reuse, comparative analyses and extraction of new findings from published data. This process has been mainly driven by journal publication guidelines and funding agencies. However, there is a need for better integration of public repositories and coordinated sharing of all the pieces of information needed to represent a full mass spectrometry (MS)–based proteomics experiment. …In this Correspondence, we report the first implementation of the ProteomeXchange consortium, an integrated framework for submission and dissemination of MS-based proteomics data."  Read full text.

Recent Articles

  • Drs. Naeha Subramanian, Leah Rommereim Gilmore, and Ajay Suresh Akhade

    Small, Persistent Increase in the Expression of NOD1 May Promote Cancer Risk

    ISB researchers have found that a small, persistent increase in the expression of NOD1 could be responsible for higher cancer risks. The research team found that a slight 1.5-fold uptick in NOD1 expression can activate the protein and downstream signaling pathways in a manner similar to vast (30- to 200-fold) overexpression.

  • CRI iAtlas

    CRI iAtlas Expands to Interactive Analysis of Data on Immunotherapy Treatments

    CRI iAtlas is a comprehensive web-based resource that allows oncologists and researchers to study and analyze interactions between tumors and the immune microenvironment. The iAtlas team released immuno-oncology modules that allow investigators to access and work with genomics data from trials of treatment with immune-checkpoint inhibitors.

  • Last-Minute Gift Ideas: 2020 Edition

    Wait, what day is it? What month is it? This year has been a doozy. The pandemic has fundamentally changed our lives, and at times, has made us feel like we’re in a real-life Groundhog Day. Well, if you’ve found yourself in the last-minute shopping scramble, we’re back with a half dozen solid ideas that we hope will make your gift-giving life easier.